Mutations in receptor tyrosine kinase (RTK) growth factor receptors (epidermal growth factor receptor, platelet-derived growth factor receptor, MET and ERBB2), which result in downstream activation of the RAS/RAF/MEK/ERK mitogen-activated protein kinase (MAPK) pathway and PI(3)K/Akt pathway, are found in almost all high-grade gliomas and MAPK signaling is necessary for continued glioma maintenance. In addition, BRAF is mutated in the majority of low-grade gliomas and its expression and activity is significantly increased in the majority of high-grade gliomas. Although the importance of RTKs and RAS signaling in glioma development has been shown, the role of BRAF has yet to be characterized. We evaluated the effect of activated BRAF in glioma formation using the retroviral replicationcompetent avian leukosis virus long terminal repeat, splice acceptor (RCAS)/TVA system to transfer genes encoding activated forms of BRAF, KRas, Akt and Cre to nestinexpressing neural progenitor cells in Ink4a/Arf lox/lox mice in vivo. Although expression of activated BRAF alone is not sufficient for tumorigenesis, the combination of activated BRAF and Akt or BRAF with Ink4a/Arf loss is transforming. Interestingly, activated BRAF generates gliomas with characteristics similar to activated KRas in the context of Akt but not Ink4a/Arf loss. Our studies show a role for BRAF activation and signaling in glioma development and as potential target for glioma therapy.
Introduction
Gliomas are named according to the type of cell they most closely resemble (Hill et al., 1999) and subcategorized according to their grade by the World Health Organization (WHO) (Louis et al., 2007) . Recently, a novel BRAF-KIAA1549 fusion gene was discovered in 66% of pilocytic astrocytomas (PAs; WHO grade I) and BRAF V600E mutations were found in 2% of PAs (Jones et al., 2008) . BRAF V600E mutations have also been identified in 6% of glioblastoma multiforme (GBM), the highest grade of glioma (WHO grade IV) (Basto et al., 2005) , and in 11% of glioma cell lines (Davies et al., 2002) . In addition, a recent study showed a 5-fold increase in RAF serine/threonine kinase activity in a significant series of GBM coupled with a 12-fold increase in BRAF and a twofold increase in CRAF protein levels (Lyustikman et al., 2008) . Consistent with these findings, copy number gains including the BRAF locus, 7q35, occur in as many as 63% of anaplastic astrocytomas (grade III) and grade IV tumors (Jeuken et al., 2007) . However, the role of BRAF activation in glioma formation has not yet been evaluated.
Owing to alternative splicing and differential usage of at least two initiating codons, both mouse and human BRAF genes can encode as many as ten different BRAF protein isoforms with molecular weights ranging from 65 to 105 kDa. However, in neural tissues, the predominant forms are of higher molecular weight (Barnier et al., 1995) . This is also the case in human GBM tissue (Lyustikman et al., 2008) . Inactivating mutations in the Akt signaling repressor, phosphatase and tensin homolog deleted on chromosome ten (PTEN), are also common and occur in over 70% of grade IV tumors. In the absence of PTEN, Akt activity is elevated leading to increased proliferation and inhibition of apoptosis. Akt activation has also been documented in GBM as a result of increased phosphatidylinositol 3-kinase (PI3K) activity due to mutations within the regulatory subunit of PI3K (PIK3CA) (Mizoguchi et al., 2004) . Mutations that inactivate both the pRb and p53 pathways are found in 78% and 87% of grade IV tumors, respectively (for example, MDM2, CCND2, CDKN2C, CDK6, CDKN2A, CDK4, RB and TP53) (Furnari et al., 2007) . The CDKN2A locus encodes two protein products, INK4a and ARF. INK4a blocks pRb phosphorylation and prevents progression from the G 1 to S phase in the cell cycle, whereas ARF is involved in the regulation of p53 levels (Chin et al., 1998; Roussel, 1999) and acts to arrest the cell cycle in G1 and G2 phases in response to oncogenic stimuli (Quelle et al., 1995) . Mutations in receptor tyrosine kinase (RTK) growth factor receptors (epidermal growth factor receptor, platelet-derived growth factor receptor, MET and ERBB2) resulting in constitutive downstream signaling of the canonical mitogen-activated protein kinase (MAPK) (for example, RAS/RAF/MEK/ERK) and PI3K/Akt pathways are found in almost all astrocytic tumors.
We and others have used a somatic cell gene delivery method based on the replication-competent avian leukosis virus long terminal repeat, splice acceptor (RCAS)/TVA system to induce gliomas in mice that express the TVA receptor under the control of the nestin promoter (N-TVA) (Holland et al., 2000; Holmen and Williams, 2005) . The combined expression of mutant KRas with either Akt activation or deletion of the Ink4a/Arf locus in nestin-expressing neural progenitor cells leads to the development of GBM in mice (Holland et al., 2000; Uhrbom et al., 2002) . Mutations in CRAF, also known as RAF-1, are largely restricted to leukemias; however, a novel CRAF fusion gene was recently identified in 2% of PA (Jones et al., 2009 ) and activated CRAF can substitute for KRas in combination with Akt activation or Arf loss to induce GBM in mice (Lyustikman et al., 2008) .
In this study, we used the RCAS/TVA model to assess the role of activated BRAF in glioma development in vivo. We show that, although BRAF V600E is not tumorigenic on its own, cooperation with Ink4a/Arf loss or activation of Akt leads to the formation of gliomas in this model. The BRAF V600E /Akt tumors resembled KRas G12D Akt tumors in their histological appearance, incidence and lethality. In contrast, BRAF
V600E -and KRas

G12D
-induced tumors differed significantly in the context of Ink4a/Arf deficiency. These results show that BRAF has a role in glioma formation that is context dependent. Owing to the high incidence of BRAF mutations in low-grade gliomas (Jones et al., 2008; Pfister et al., 2008) , overexpression and mutation of BRAF in high-grade gliomas (Basto et al., 2005; Jeuken et al., 2007) , and the importance of the RAS/MAPK pathway in glioma maintenance (Holmen and Williams, 2005) , our findings suggest that BRAF may be a relevant target for therapy in the majority of glioma patients.
Results
Confirmation of stable gene delivery into cultured astrocytes Astrocytes were isolated from N-TVA/Ink4a/Arf lox/lox mice, established in culture and infected with a replication-competent avian leukosis virus long terminal repeat, splice acceptor, Bryan polymerase-containing vectors of envelope subgroup A (RCASBP(A)) virus encoding Cre to delete the Ink4a/Arf locus (Supplementary Figure 1 ). After the loss of Ink4a/Arf, these cells proliferated continuously and never experienced a detectable senescence crisis even after 30 population doublings, suggesting they are immortal. This is consistent with the behavior of astrocytes isolated from glial fibrillary acidic protein (GFAP)-TVA mice that had been crossed to mice that are germline deficient for Ink4a/Arf (Holland et al., 1998b) . The immortal astrocytes were used to evaluate the expression and activity of KRas
G12D
, Akt and BRAF V600E (isoform B1) alone and in combination. BRAF isoform B1 contains exons 1-18 but does not contain exons 8b or 9b, which have opposing effects on transformation (Hmitou et al., 2007) . The delivery and expression of BRAF V600E in astrocytes in culture by infection with RCASBP(A)B-RAF V600E was observed to be at a similar level and molecular weight to that seen in human GBM cells lines (Supplementary Figure 2) . The efficiency of RCASB-P(A) infection in N-TVA astrocytes was assessed using RCASBP(A)GFP (Figure 1a) . Nearly all of the cells expressed GFP indicating productive infection. Western blot analysis of cell lysates showed viral KRas G12D , BRAF V600E and Akt expression in infected astrocytes (Figure 1b) . To ensure that RCASBP(A)BRAF V600E and RCASBP(A)KRas G12D were both active, we evaluated the levels of phoshporylated ERK 1/2 (P-ERK) following serum starvation. Both constructs induced similar levels of P-ERK, indicating that they were equally active. As a consequence of the negative regulatory effects of Akt on BRAF, less P-ERK was observed in RCASBP(A)BRAF
V600E
-infected cells that were also infected with RCASBP(A)Akt (Figure 1b) . The levels of total ERK remained unchanged between the different conditions.
KRas or BRAF activation induces anchorage-independent growth of astrocytes in vitro when combined with Ink4a/ Arf loss or Akt activation The ability of the mutant Ras and BRAF to induce anchorage-independent growth of astrocytes was initially assayed in vitro by colony formation in soft agar. Although RCASBP(A)Cre or RCASBP(A)GFP infected astrocytes were unable to grow in soft agar, Ink4a/Arf-deficient astrocytes expressing activated KRas G12D or BRAF V600E formed numerous colonies in soft agar, showing that activation of this pathway in astrocytes results in anchorage-independent growth, a characteristic of transformed cells. Ink4a/Arf wild-type astrocytes infected with RCASBP(A)Akt alone did not form colonies in soft agar but coexpression with activated KRas G12D or BRAF V600E induced anchorageindependent growth, showing the ability of these oncogenes to cooperate with Akt activation or Ink4a/ Arf loss in vitro (Supplementary Figure 3) . Figure 1c ). It has previously been established that infection with RCASBP(A) KRas G12D or Akt alone is insufficient for tumorigenesis in N-TVA mice (Holland et al., 2000) . No mice infected with BRAF V600E (0/28) or Cre (0/10) alone developed tumors. In addition, there is no significant incidence of brain tumors in N-TVA/Ink4a/Arf-null mice under 100 days of age and deletion of the Ink4a/Arf locus alone is insufficient for tumorigenesis within this time period (Serrano et al., 1996; Sharpless et al., 2001) .
Gliomas induced by BRAF in the context of Ink4a/Arf deficiency are distinct from those induced with activated Akt Tumors arising in mice infected with Akt and KRas G12D or BRAF V600E resembled highly invasive GBM (WHO grade IV) histologically; both possessed a diffuse growth pattern and contained large confluent geographical necrosis that is well demarcated from the viable tumor (Figures 2 and 3 ). In the context of activated Akt, BRAF V600E tumors were extremely pleomorphic, and contained a spectrum of cellular morphology ranging from very small round cells to spindle cells and giant cells (Figure 2 ). KRas G12D tumors were typically more glial in appearance ( Figure 3 ) and showed extremely pronounced angiogenesis compared with the other tumors in the context of activated Akt (Figure 2 ). In contrast, KRas G12D tumors arising in the context of Ink4a/Arf deficiency were much less necrotic than Akt/KRas G12D tumors and possessed a spindle-cell tumor morphology with a diffuse and monotonous growth pattern that lacked prominent vascular proliferation. These tumors were relatively well demarcated and not infiltrative, but invasion was seen to progress through the subarachnoid or the Virchow-Robin perivascular space (Figure 2 ). The phenotype of tumors arising in mice expressing BRAF V600E in the absence of Ink4a/Arf was typified by a diffuse monotypic and monomorphic growth pattern with the tumors cells showing angulated pleomorphic nuclei. These tumors did not possess a prominent vasculature and there was no evidence of necrosis. They grew into the subarachnoid space but were well demarcated and not infiltrative (Figure 2 ). Despite the significant histological differences between the tumors arising in mice infected with Akt and KRas G12D , Akt and BRAF
, or Cre and BRAF
, there was no significant difference in tumor incidence, latency or lethality (Po0.1). In contrast, both tumor lethality and penetrance were significantly higher Lysates were separated on a 4-20% Tris-glycine polyacrylamide gel, transferred to nitrocellulose, and probed with antibodies directed against V5 (BRAF), hemagglutinin (HA) (Akt), pan-RAS (KRas), phoshporylated Erk (P-Erk) or total Erk (Erk) as indicated. The membrane was re-probed with an antibody against a-tubulin (bottom) to ensure equal loading. The Ras blot shows endogenous Ras (lower band) and the virally delivered KRas (upper band). The virally delivered KRas is a higher molecular weight as a result of the FLAG epitope tag. (c) Kaplan-Meier percent survival curve. N-TVA/Ink4a/Arf lox/lox mice were injected with the indicated viruses at birth. Censored survival data were analysed using a log-rank test of the Kaplan-Meier estimate of survival. No tumors were observed in mice injected with BRAF V600E or Cre alone (n ¼ 36) (solid black line), and it has previously been shown that no tumors form in mice injected with either KRas G12D or Akt alone (Holland et al., 2000) . There was no significant difference in survival between . Interestingly, P-Erk reactivity was strongest in tumor cells at the leading edge and low or absent within the center in Cre/BRAF V600E tumors. Tumor vasculature was assessed by IHC using an antibody to endomucin (Figures 6e-h) . The Akt/ KRas G12D tumors were highly vascular but the vessels were abnormal (Figures 6e). Assessment of cellular proliferation using IHC for the cellular proliferation marker Ki67 showed that all of the tumors were highly proliferative regardless of context (Figures 6i-l) . IHC for the neuronal differentiation marker, synaptophysin, was performed to rule out the possibility that the Cre/ BRAF V600E tumors were primitive neuroectodermal tumors (Supplementary Figure 5) . A summary comparison of glioma morphology and histology is provided in Supplementary Table 1.
Discussion
In the context of activated BRAF, loss of Ink4a/Arf seems to be equivalent to gain of Akt in this model. Infection of neural progenitor cells expressing TVA under the control of the nestin promoter in Ink4a/Arf lox/lox mice by RCASBP(A)Cre causes a deletion of the Ink4a/ Arf locus leading to immortalization, loss of cell cycle control, and tumor growth in the presence of activated MAPK (Sharpless et al., 2001; Uhrbom et al., 2002 Uhrbom et al., , 2005 . Similarly, activation of Akt in these cells also promotes tumor growth in the presence of activated MAPK (Holland et al., 2000; Holmen and Williams, 2005) . Akt signaling inhibits apoptosis and promotes proliferation through phosphorylation/inactivation of Bad, forkhead transcription factors and caspase-9. Akt also regulates the cell cycle by preventing GSK-3b-mediated phosphorylation and degradation of oncogenes, including b-catenin, cyclin D1, cyclin E, p21 V600E þ Cre, (e and f) KRas G12D þ Akt and (g and h) KRas G12D þ Cre. Although the CNS border was well defined (g and h) and the tumors were not infiltrative, invasion was seen to progress through the subarachnoid space and Virchow-Robin perivascular spaces (arrow, h). Scale bars represent 500 mm.
and Myc (Lizcano et al., 2000) . Akt activates protein synthesis and inactivation of the eIF4BP1 leading to angiogenesis in both HIF-dependent and -independent pathways through TSC2, mTOR, p70S6 kinase and VEGF (Mizoguchi et al., 2004; Riemenschneider et al., 2006) .
Tumors induced by BRAF V600E in the context of Ink4a/Arf deficiency lack the hallmarks of diffuse infiltration, necrosis and aberrant vascularization normally ascribed to aggressive gliomas. They do not express the glial differentiation markers GFAP or S100, or the oligodendrocyte differentiation marker Olig2 (Dai et al., 2005) , but strongly express the stem cell marker nestin, suggesting that they have remained in an undifferentiated state. In contrast, BRAF V600E tumors in the context of activated Akt more closely resemble GBM and are more similar to Akt/KRas G12D tumors, albeit with less vascularity. Akt pathway activation also promotes astrocytic differentiation further explaining the differences in morphology between Akt-and Creinduced Ink4a/Arf-null tumors (Dai and Holland, 2003; Hu et al., 2005) . Although Cre/KRas G12D tumors were distinct from Cre/BRAF V600E tumors, they were more similar to Akt/BRAF V600E than Akt/KRas G12D tumors in terms of the level of invasion and necrosis observed. Both the BRAF V600E and KRas
G12D
Ink4a/Arf-null tumors were considerably more proliferative than the Akt tumors. This is not surprising as they have lost control over both cell cycle progression and arrest as a result of p53 and pRb pathway inactivation. Furthermore, the presence of angulated pleomorphic nuclei and strong nestin immunoreactivity suggests that these tumors are not benign low-grade lesions, but aggressive gliomas. High nestin expression is typically found in malignant high-grade primary brain tumors, whereas lower-grade gliomas express low levels of nestin (Dahlstrand et al., 1992) . It is possible that infection of nestin-expressing neural progenitor cells with viruses containing BRAF V600E and activated Akt induces astrocytic differentiation. In view of the fact that human gliomas differ markedly in grade and histological appearance, it is not surprising that gliomas induced with different oncogenes give rise to tumors with distinct histology. Although BRAF V600E and KRas G12D both promote glioma formation through MAPK activation, KRas activates additional downstream effectors also known to be dysregulated in GBM (for example, PI3K and RAL). These differences in regulation and downstream effectors may explain the different morphology seen between the BRAF V600E -and KRas
-induced gliomas particularly, as several RAS effectors have roles in hypoxia and vascular growth.
It is interesting to note that tumors induced by BRAF V600E in the context of Ink4a/Arf deficiency are quite different from tumors induced by active CRAF in the context of Arf loss (Lyustikman et al., 2008) . The CRAF Arf-null tumors presented with histological features similar to GBM, which are absent in BRAF
V600E
Ink4a/Arf-null tumors. The CRAF tumors are described as having a 'spindle-cell sarcoma-like morphology' containing pronounced angiogenesis, giant cells, and 'pseudopalisading necrosis' common to GBM. KRas
G12D
Arf-null tumors showed the same phenotype and both tumor types expressed GFAP and nestin (Lyustikman et al., 2008) . As the phenotype of the KRas G12D Arf-null tumors is similar to what we observed with KRas G12D in the absence of both Ink4a and Arf, the additional loss of Ink4a in our experiments is unlikely to be the cause of the phenotypic differences between BRAF V600E and activated CRAF. Genetic studies in mice have shown that the RAF proteins have nonredundant functions in development, which suggests that the different isoforms perform distinct functions (Pritchard et al., 1996; Wojnowski et al., 1997 Wojnowski et al., , 1998 . In addition, there are known differences in how the RAF proteins are regulated. Phosphorylation of S338 and Y341 by Src in the N-region is required for activation of CRAF by Ras (Chong et al., 2001) . These sites are not conserved in BRAF, which is constitutively phosphorylated allowing activation by Ras alone (Wellbrock et al., 2004) . BRAF contains three negative regulatory Akt phosphorylation sites (Ser365, Ser429 and Thr440), Akt signaling reduces BRAF activity and inhibition of Akt with the PI3K inhibitor LY294002 leads to increased BRAF activity (Guan et al., 2000) . These sites are absent in CRAF (Guan et al., 2000) and the CRAF mutant studied, 22W (Stanton et al., 1989) , lacks the N-terminal 305 amino acids, which contain the CR1 and CR2 regulatory domains (Wellbrock et al., 2004) . Therefore, it is highly likely that there are significant differences in the signaling activity of the mutants studied.
Primary glioblastoma, giant cell glioblastoma and gliosarcoma, a glioblastoma subtype with focal aberrant mesenchymal differentiation, differ in both their histological appearance and mutation spectrum (Jones et al., 1991; Paulus and Jellinger, 1992; Reis et al., 2000) . Our results suggest that a high degree of Akt activation may be necessary for giant cell formation, as this phenotype was only observed in the presence of activated Akt and these cells showed strong Akt immunoreactivity. In contrast, the cells of KRas G12D Ink4a/Arf-null tumors were spindle-cell-like in appearance and did not show GFAP reactivity, which is frequently seen in areas of gliosarcomas and spindle-cell gliomas (Uhrbom et al., 2002) . Tumor vasculature was more prominent in KRas
-and Akt-induced tumors than KRas G12D Ink4a/Arf-null tumors; however, this vasculature was highly abnormal and not necessary for tumor development as the Ink4a/Arf-null tumors contained a wellordered vasculature with much less necrosis than the Akt tumors.
Despite the common occurrence of BRAF mutations in PAs, none of the BRAF V600E tumors resembled PA in appearance or grade. The BRAF-KIAA1549 fusion gene found in the majority of PAs shows a deletion of either two or all three of the negative regulatory Akt consensus phosphorylation sites, which results in elevated BRAF kinase activity (Jones et al., 2008) and this may be partly responsible for the morphological differences. Moreover, mutations that target the p53 pathway are seen in low-grade astrocytomas and loss of p53 function can act as an initiating event in astrocytoma pathogenesis (Marino et al., 2000; Ohgaki and Kleihues, 2007) . pRb pathway inactivation and Akt activation are typically only seen in high-grade glioma (Hamel et al., 1993; Ohgaki and Kleihues, 2007) and loss of pRb function is considered to be involved in the progression from benign to highly malignant astrocytomas (Kleihues et al., 1993) . It is likely that BRAF V600E activation of the MAPK pathway in combination with Ink4a/Arf loss prevents or provides no signal for differentiation leaving the cells in an immature state.
Cancers with BRAF mutations often evolve to become addicted to this signaling pathway. Given that inhibition of RAF or MEK in melanoma cells lines with BRAF mutations causes the cells to undergo G1 arrest and leads to apoptosis through Bim and Bmf activation (VanBrocklin et al., 2009) , combination therapy with RAF or MEK inhibitors and a BH3 mimetic (for example, ABT-737) may prove beneficial. On the other hand, MEK/ERK signaling represents only one arm of the tumor growth and survival network in gliomas with Ras or RTK mutations, and in many cases the ERK and PI3K pathways regulate a common set of downstream apoptotic regulators (for example, Bad, Mcl-1, Bcl-x L and Bcl2) (Balmanno and Cook, 2009) . In these cases, the combination of a BH3 mimetic with MEK/RAF and PI3K inhibitors may prove necessary.
In conclusion, BRAF V600E can substitute for Ras mutations in the development of GBM when combined with Akt. In contrast, BRAF V600E tumors induced in the context of Ink4a/ArfÀ deficiency do not resemble GBM, but are highly malignant. Owing to the high expression of RAF proteins in high-grade glioma, the incidence of BRAF mutations in low-grade gliomas and the reliance of these tumors on active ERK/MAPK signaling for survival (Holmen and Williams, 2005) , inhibition of RAF or MEK may represent an appropriate therapeutic strategy for gliomas with altered BRAF activity.
Materials and methods
Transgenic mice
Nestin-TVA (N-TVA) mice have been described (Holland et al., 1998a) and were purchased from the Van Andel Research Institute mouse repository. Ink4a/Arf lox/lox mice have also been described and were a kind gift from Ronald DePinho (Aguirre et al., 2003) . All experiments were performed in compliance with the 'Care and Use of Animals' and were approved by the IACUC before experimentation.
Vector constructs
The retroviral vectors used in this study were RCASBP(A) (Holmen et al., 1999) . RCASBP(A)KRas G12D and RCASB-P(A)Akt have been previously described (Holland et al., 2000; Holmen and Williams, 2005) . The N-terminus of KRas has a FLAG epitope tag and Akt contains an HA epitope tag at the C-terminus. The Akt used is the activated form designated Akt-Myr D11-60 (Holland et al., 2000) . RCASBP(A)Cre was a gift from Eric Holland (MSKCC) and the pCDNA3.1 constructs containing human wildtype (NM_04333.4) and BRAF V600 were gifts from Martin McMahon (UCSF). To generate pENTR3C-BRAF-wt and BRAF V600E , the pCDNA3.1-BRAF constructs were digested with Pme I and the 2.4-Kb BRAF fragments were cloned into pENTR3C (Invitrogen, Carlsbad, CA, USA) digested with Dra I and Eco RV. A V5 epitope tag was inserted at the C-terminus of BRAF V600E by cloning the 1.8-Kb Kpn I and Xba I fragment into pCDNA6/V5HisA (Invitrogen) cut with the same enzymes. The fragment along with the V5 sequence was excised as a Kpn I-Pme I fragment and inserted back into pENTR3C-BRAF V600E digested with Xba I, filled in with Klenow, and digested with Kpn I. RCASBP(A)BRAF V600E -V5 was generated by mixing pENTR3C-BRAF V600E -V5 with the RCASBP(A) destination vector in the presence of the LR Clonase Enzyme Mix (Invitrogen, Carlsbad, CA, USA) as described (Bromberg-White et al., 2004) .
Cell culture DF-1 cells were grown in Dulbecco's modified Eagle's medium-high glucose supplemented with 10% fetal bovine serum (FBS) (Hyclone, Logan, UT, USA), 1 Â penicillin/ streptomycin, and maintained at 39 1C (Schaefer-Klein et al., 1998) . Primary astrocytes were isolated from the brains of nestin-TVA-positive newborn mice. Single cells were obtained by mincing the tissue followed by digestion in 0.05% trypsin (Invitrogen) for 30 min at 37 1C. The cells were resuspended in RPMI 1640 (Invitrogen) with 5% FBS and 1 Â penicillin/ streptomycin (Invitrogen).
Growth in soft agar
To assess anchorage-independent growth, 1.5 Â 10 5 cells were suspended in 0.35% Difco agar noble (Becton Dickinson, Sparks, MD, USA) in RPMI with 10% FBS and layered over pre-solidified 0.65% Difco Noble Agar in RPMI with 10% FBS per well of a six-well dish. Each cell line was assayed in triplicate.
Virus propagation
Virus infection was initiated by calcium phosphate transfection of plasmid DNA that contained the proviral retroviral vector. In standard transfections, DF-1 cells were plated at 30% confluency, allowed to attach (2-3 h), and 10 mg of purified plasmid DNA was introduced by the calcium phosphate precipitation method as previously described (Holmen et al., 1999) . Viral spread was monitored by assaying culture supernatants for avian leukosis virus capsid protein by enzyme-linked immunosorbent assay as previously described (Smith et al., 1979) .
Viral infections in vitro
Astrocytes were seeded in six-well plates at a density of 5 Â 10 4 cells/well and were maintained in RPMI 1640 with 5% FBS and 1 Â penicillin/streptomycin at 37 1C. After the cells attached, the medium was removed and replaced with 1 ml of filtered virus-containing medium in the presence of 8 mg/ml polybrene (Sigma, St Louis, MO, USA) for 2 h at 37 1C. The virus was removed and replaced with fresh medium, and the cells were incubated at 37 1C for 1 h. Cells were infected again for another 2 h, after which the virus-containing medium was replaced with fresh medium and the cells were incubated overnight at 37 1C.
Viral infections in vivo
The N-TVA line was crossed to Ink4a/Arf lox/lox mice, to generate N-TVA/Ink4a/Arf lox/ þ mice. These mice were then intercrossed to generate N-TVA/Ink4a/Arf lox/lox mice. The lox sites flank exons 2 and 3 of this locus such that Cre-mediated excision eliminates both p16 INK4A and p19
ARF
. Infected DF-1 cells from a confluent culture in a 10-cm dish were trypsinized, pelleted, resuspended in 50 ml PBS, and placed on ice. Newborn N-TVA/Ink4a/Arf lox/lox mice were injected intracranially 2-mm ventral from the bregma (intersection of the coronal and sagittal sutures) with 5 ml of infected DF-1 cells using a gas-tight Hamilton syringe. Cohorts were injected with RCASBP(A)BRAF V600E or RCASBP(A)KRas G12D alone or in combination with RCASBP(A)Cre or RCASBP(A)Akt. Censored survival data were analysed using a log-rank test of the Kaplan-Meier estimate of survival.
Western blotting
Western blots were immunostained for Akt-HA using an anti-HA monoclonal antibody (HA.11, Covance, Berkeley, CA, USA) at a 1:1000 dilution; for BRAF V600E -V5 using a mouse monoclonal antibody targeting V5 (R960-25, Invitrogen) at a 1:1000 dilution; for KRas G12D using a pan-RAS antibody (05-516, Millipore, Temeculah, CA, USA) diluted 1:1000 and antia-tubulin (T9026, Sigma) at a 1:5000 dilution. Detection of MAPK activation was performed using a 1:1000 dilution of a rabbit monoclonal antibody directed against phosphorylation of Erk at Thr202 and Tyr 204 (4370, Cell Signaling, Boston, MA, USA). Detection of total Erk protein levels was performed using a 1:5000 dilution of anti-Erk antibody (9102, Cell Signaling). Detection of BRAF was performed using a 1:1000 dilution of anti-BRAF antibody (9434, Cell Signaling). The blots were then incubated with an anti-mouse or rabbit IgG-HRP secondary antibody diluted 1:2000 (Cell Signaling) for 1 h at room temperature. The blots were incubated with ECL (Amersham, Piscataway, NJ, USA), and exposed to film.
IHC
Tissues were paraffin embedded and 5-mm sections were adhered to glass slides. The sections were stained with hematoxylin and eosin or left unstained for IHC. Antigen retrieval was performed in 'Diva Decloaking' buffer (Biocare medical, Concord, CA, USA) by boiling for 10 min. The sections were then treated with 3% hydrogen peroxide and blocked in Background Sniper (Biocare medical) for 10 min. Primary antibodies were diluted in Renaissance background reducing diluent (Biocare medical). The sections were incubated overnight at 4 1C and probed with Mach 4 rabbit polymer reagent (Biocare medical) or Mach 4 mouse probe for 15 min followed by Mach 4 polymer for 15 min for mouse monoclonal antibodies. Visualization was carried out with DAB (Biocare medical). Akt expression was detected using an antibody to the HA epitope (HA.11, Covance) (diluted 1:1000). BRAF expression was detected using an antibody to the V5 epitope (Invitrogen) (diluted 1:200). Cell proliferation was detected using an antibody to Ki67 (M7246, Dako, Carpinteria, CA, USA) (diluted 1:50). The following additional antibodies were used at a 1:200 dilution: GFAP (ab7260, Abcam, Cambridge, MA, USA), Olig2 (ab33427, Abcam), nestin (ab6142, Abcam), p19 ARF (ab80, Abcam), synaptophysin (ab32127, Abcam), S100 (Z0311, Dako) and Endomucin (sc65495, Santa Cruz Biotechnology, Santa Cruz, CA, USA). Ras expression was detected using an antibody to the FLAG epitope (M2, Sigma). Detection of MAPK activation was performed using a 1:100 dilution of a phospho-Erk antibody (4370, Cell Signaling).
